The target of the more proximal (17p13.1) 17p change could be TP53. Indeed, loss at 17p is the most common genetic alteration thus far detected in ovarian cancer, with mutation rates as high as 50% in advanced stage carcinomas [46]. Here, TP53 is linked to ovarian cancer.